ArticleHaemophilia : the official journal of the World Federation of Hemophilia
Lifetime Cost-Utility Analysis of Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors in China: A Markov Model Analysis.
Article in Haemophilia : the official journal of the World Federation of Hemophilia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimAs emicizumab shares no sequence homology with factor VIII (FVIII), in patients with haemophilia A, haemostasis can be restored irrespective of the presence of FVIII inhibitors. Emicizumab, therefore, substantially improved previously available prophylactic options. This study aims to evaluate the cost-effectiveness of using emicizumab prophylaxis therapy compared to recombinant FVIII (rFVIII) prophylaxis for the treatment of severe haemophilia A.
methodsA Markov model from a Chinese healthcare system perspective using annual cycles was constructed to evaluate the lifelong costs and effectiveness. All patients started at age zero in a non-inhibitor state, treated with either emicizumab or rFVIII prophylaxis. On-demand rFVIII was given upon breakthrough bleeding for both groups. A part of severe patients developed FVIII inhibitors resulting from on-demand treatment. For patients with inhibitors, those previously treated with rFVIII prophylaxis switched to a recombinant activated factor VII (rFVIIa) on-demand only therapy, whereas those previously on emicizumab kept the same prophylactic regimen with rFVIIa for breakthrough bleeds. One immune tolerance induction (ITI) was allowed to eradicate inhibitors. Model inputs, including utility values, bleeding rates, adverse event rates and the success rate of ITI were from HAVEN 1 and 3 trials and the other literature.
resultsThe results of both the 0-12 age group and lifetime simulations demonstrated a dominant economic advantage of emicizumab prophylaxis over rFVIII prophylaxis therapy.
conclusionSevere haemophilia A patients treated by emicizumab prophylaxis can benefit both patients' QoL and economic outcomes compared to those treated by rFVIII prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.